Your browser doesn't support javascript.
loading
Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor.
Hennen, Stephanie; Kodra, János T; Soroka, Vladyslav; Krogh, Berit O; Wu, Xiaoai; Kaastrup, Peter; Ørskov, Cathrine; Rønn, Sif G; Schluckebier, Gerd; Barbateskovic, Silvia; Gandhi, Prafull S; Reedtz-Runge, Steffen.
Afiliação
  • Hennen S; Incretin Biology, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Kodra JT; Protein &Peptide Chemistry 3, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Soroka V; Protein Structure, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Krogh BO; Yeast Expression Systems, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Wu X; Protein Chemistry 1, Novo Nordisk A/S, Novo Nordisk China R&D, Beijing, China.
  • Kaastrup P; Antibody Technology, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Ørskov C; Incretin Biology, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Rønn SG; Incretin Biology, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Schluckebier G; Protein Structure, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Barbateskovic S; Protein Structure, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Gandhi PS; Protein Interaction, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Måløv, Denmark.
  • Reedtz-Runge S; Protein Structure, Novo Nordisk, Novo Nordisk Park, DK-2760, Måløv, Denmark.
Sci Rep ; 6: 26236, 2016 05 19.
Article em En | MEDLINE | ID: mdl-27196125
ABSTRACT
The Glucagon-like peptide-1 receptor (GLP-1R) is a member of the class B G protein-coupled receptor (GPCR) family and a well-established target for the treatment of type 2 diabetes. The N-terminal extracellular domain (ECD) of GLP-1R is important for GLP-1 binding and the crystal structure of the GLP-1/ECD complex was reported previously. The first structure of a class B GPCR transmembrane (TM) domain was solved recently, but the full length receptor structure is still not well understood. Here we describe the molecular details of antibody-mediated antagonism of the GLP-1R using both in vitro pharmacology and x-ray crystallography. We showed that the antibody Fab fragment (Fab 3F52) blocked the GLP-1 binding site of the ECD directly and thereby acts as a competitive antagonist of native GLP-1. Interestingly, Fab 3F52 also blocked a short peptide agonist believed to engage primarily the transmembrane and extracellular loop region of GLP-1R, whereas functionality of an allosteric small-molecule agonist was not inhibited. This study has implications for the structural understanding of the GLP-1R and related class B GPCRs, which is important for the development of new and improved therapeutics targeting these receptors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor do Peptídeo Semelhante ao Glucagon 1 / Anticorpos Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor do Peptídeo Semelhante ao Glucagon 1 / Anticorpos Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Dinamarca